Teva Pharmaceutical Industries Ltd (TEVA), a leading global pharmaceutical company, has seen significant changes in its stocks. While the stocks crashed on one occasion, it soared remarkably in another reaching a six-year high primarily due to a win with a
Sanofi-tied drug. The company showed strength with its stocks jumping by 26.5% and has been touted as outpacing its medical peers.
UBS Group analyst predicted a rise in TEVA's stock price, maintaining a 'Buy' rating and lifting the stock price target to $30. This follows the company's stocks defying market bloodbath and passing above the 200-day average. Despite a 7% fall after Q3 earnings exceeding expectations and guidance increases,
Teva stock is later seen surging amid strong buy ratings and soaring to 52-week highs multiple times. Amid this, Teva had to pay $450 million to resolve US kickback and price-fixing cases. A key deal with IBD drug leader Catalyst propelled its stocks further up. The revenues soared by 13% to $4.3B in Q3, and the prospects appear bullish after the company scored success with UC Drug. Despite some hurdles like losing a US appeal to keep inhaler patents on the FDA protected list, the overall outlook for Teva remains positive.
Teva Pharmaceutical Stocks News Analytics from Tue, 04 Jun 2024 07:00:00 GMT to Fri, 24 Jan 2025 13:04:01 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor 4
